Temporary stopping MTX improves immunogenicity of influenza vaccination
KEY POINT
In patients with rheumatoid arthritis (RA), holding the methotrexate (MTX) dose for 2 weeks after administration of the seasonal influenza vaccine improved vaccine response compared with patients who continued MTX treatment, according to results of a randomized trial published in BMJ.
SOURCES
Park JK, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. BMJ. 2018;[Epub ahead of print].
Singh JA, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
